Source:http://linkedlifedata.com/resource/pubmed/id/10740640
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2000-4-7
|
pubmed:abstractText |
TZT-1027 was evaluated for its antitumor effects in sixteen human tumors xenografted in nude mice from gastric (H-81, H-106, H-30, H-154), breast (H-31, H-62), colon (H-110, H-143), lung (LC-376, H-74, Mqnu-1, LC-351), liver (H-181), renal cell (H-12) and ovarian (H-OC-3, SOC-4) cancer lines. In the latter three and lung (Mqnu-1, LC-351) cancers the results were compared with those obtained with CPT-11, VCR, CDDP, ADM. TZT-1027 showed effective antitumor activity (IR > or = 58%) against fifteen of the tumor lines, all but LC-351, and showed markedly effective activity (IR > or = 80%) against twelve tumor lines, including drug-resistant colon (H-110), lung (H-74) and ovarian (SOC-4) cancer lines. The complete regression was shown in five H-OC-3 tumor-bearing mice out of seven. Moreover, TZT-1027 was shown to be more potent in three cancer models (Mqnu-1, H-81, SOC-4) than CPT-11, and to have markedly effective antitumor activity in two cancers (H-12, H-OC-3) in which VCR was ineffective and in ovarian cancer (SOC-4) in which CPT-11, CDDP and ADM were ineffective. The administration of TZT-1027 induced fewer side effects; transient reduction of body weight was observed in four lines out of sixteen tested. These results suggest that TZT-1027 is an excellent candidate for clinical trials for the treatment of cancer.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
451-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10740640-Animals,
pubmed-meshheading:10740640-Antineoplastic Agents,
pubmed-meshheading:10740640-Body Weight,
pubmed-meshheading:10740640-Breast Neoplasms,
pubmed-meshheading:10740640-Colonic Neoplasms,
pubmed-meshheading:10740640-Humans,
pubmed-meshheading:10740640-Lung Neoplasms,
pubmed-meshheading:10740640-Mice,
pubmed-meshheading:10740640-Mice, Nude,
pubmed-meshheading:10740640-Neoplasm Transplantation,
pubmed-meshheading:10740640-Oligopeptides,
pubmed-meshheading:10740640-Stomach Neoplasms
|
pubmed:year |
2000
|
pubmed:articleTitle |
[Antitumor effects of TZT-1027, a novel dolastatin 10 derivative, on human tumor xenografts in nude mice].
|
pubmed:affiliation |
Dept. of Surgery, Ueda Hospital.
|
pubmed:publicationType |
Journal Article,
English Abstract
|